LAURA BOND: Open Payments
NPI 1366749772 · ELIZABETH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$356 in 15 payments from 8 companies in 2025. Trend: 2023 $328 · 2024 $138 · 2025 $356
Food & beverage: $284Education: $72
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $155 |
| SANOFI-AVENTIS U.S. LLC | 1 | $72 |
| GENZYME CORPORATION | 2 | $37 |
| Genentech USA, Inc. | 1 | $32 |
| BioCryst US Sales Co., LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| CSL Behring | 1 | $14 |
| Organon LLC | 1 | $3 |
Products named: DUPIXENT, TEZSPIRE, BREZTRI, Xolair, ORLADEYO, FASENRA, EBGLYSS, Hizentra.
Industry payments across NJ — which companies pay providers there.
